Vir Biotechnology

US · VIR #2824 by market cap Listed 2019

11.52 -0.08 -0.69%

Live - 5344 symbols - heartbeat 401s ago · 2026-10-08 05:34

Pre-market 11.50 -0.17%

After-hours 11.52 0.00%

Overnight 11.64 +1.04%

Market cap: 1.95B
P/E (TTM): -6.51
P/B: 1.98
EPS: -3.16
Div yield: 0.00%
52W pos: 94%

Reader sentiment Are you bullish or bearish on VIR?

Anonymous reader poll. Unscientific, not investment advice.

About Vir Biotechnology

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Founded: 2016
CEO: Dr. Marianne De Backer, M.B.A.,M.Sc.,PhD
Employees: 367
Headquarters: San Francisco, California, United States of America
Fiscal year end: 12-31
Website: vir.bio

Company profile

Exchange: US
Symbol: VIR
Market-cap rank: #2824
Listing date: 2019-10-11
Market cap: 1.95B
Float cap: 1.50B
Shares out: 169.22M
Float shares: 129.82M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 05:34:05 · For reference only, not investment advice and not tailored to your situation.